“Sports TRT” Is a Steroid Cycle With Better Marketing

Francisco Cardona, MD
Francisco Cardona, MD
Internal medicine · San Antonio, Texas

The pitch is that a prescription and a clinic visit turn a performance dose of testosterone into medicine. They do not. The category is defined by the dose and the indication, not by who signed for it.

The pitch arrives with a medical vocabulary. Not a cycle, a protocol. Not steroids, optimization. Not a dealer, a men’s clinic. The dose is higher than replacement, the goal is performance and physique, and the thing that is supposed to make it different from what a bodybuilder does in a garage is that a licensed provider wrote for it.

I spent four years competing in Men’s Physique and earned my IFBB Pro card in 2017. I also prescribe testosterone every week as an internist. From both chairs, the honest description of “sports TRT” is this: it is a steroid cycle, run at a steadier dose, with a prescription attached. The prescription changes the legal exposure and the quality of the vial. It does not change the pharmacology.

The verdict in one paragraph

Replacement therapy and performance dosing are separated by the serum level you are aiming for, not by the setting. Guidelines define testosterone replacement as treating a diagnosed deficiency and targeting the middle of the normal range, roughly 450 to 600 ng/dL, using the lowest dose that gets there. Doses chosen to exceed that range are, by the Endocrine Society’s own definition in its scientific statement on performance-enhancing drugs, supraphysiologic androgen use. The health consequences that follow, erythrocytosis, suppressed fertility, cardiac remodeling, and a hypothalamic-pituitary axis that may not recover, are dose-dependent and do not care what the regimen is called.

The claimVerdictWhy
“It’s TRT because a doctor prescribed it”FalseGuidelines define the therapy by diagnosis and target range, not by prescriber. A supraphysiologic dose is supraphysiologic on a prescription pad
“Pharmaceutical-grade product makes it safe”FalseSterility and accurate concentration are real advantages over underground product. They do not change the dose-dependent effects on hematocrit, fertility or the heart
“Monitoring makes the risk manageable”Partly trueMonitoring catches erythrocytosis and allows dose reduction. It does not prevent testicular suppression, and no monitoring protocol has been shown to prevent the cardiac findings seen in long-term users
“TRAVERSE proved testosterone is cardiac-safe”OverstatedTRAVERSE tested replacement dosing, titrated to 350 to 750 ng/dL, in men with confirmed deficiency. It says nothing about performance doses in men with normal baseline levels
“Steady weekly dosing is safer than a classic cycle”Plausible, unprovenAvoiding the crash of an on-off cycle is a reasonable hypothesis. No trial has compared continuous supraphysiologic dosing against cycled dosing on hard outcomes
“It’s a steroid cycle”True, when the dose exceeds replacementSupraphysiologic androgen administration to a man who is not deficient is the textbook definition, whatever the label on the box

What testosterone replacement is, as medicine defines it

Three elements define the therapy, and all three have to be present.

A diagnosis. The American Urological Association’s guideline uses a total testosterone below 300 ng/dL as the cutoff supporting a diagnosis, measured on two separate early-morning draws, and makes the clinical diagnosis only when those low levels sit alongside symptoms or signs. [Mulhall et al., 2018] Thresholds differ a little by society. The Endocrine Society uses 264 ng/dL, the AACE has used 200. [AUANews, 2023] No society defines deficiency by how a man feels at a normal level.

A target. The AUA directs clinicians to aim for the middle third of the normal range, commonly cited as about 450 to 600 ng/dL, using the minimum dose that achieves it. The Endocrine Society’s phrasing is the mid-normal range. TRAVERSE, the FDA-mandated safety trial, titrated to 350 to 750 ng/dL. [Lincoff et al., 2023] Every one of those targets sits inside the physiologic range of a healthy man.

A monitoring schedule. Symptoms, testosterone, and hematocrit at baseline, at three to six months, then annually, with therapy held if hematocrit exceeds 54%, plus PSA assessment in men over 40. [Bhasin et al., 2018]

Notice what is absent from all of this: any provision for a man with a normal baseline who wants to be stronger. That is not an oversight. It is the boundary of the indication.

What “sports TRT” actually is

The term has no formal definition, which is part of its usefulness to the people selling it. In practice it describes one of two things.

The first is a man with a genuinely normal baseline, often 400 to 600 ng/dL, who is prescribed testosterone anyway, typically 150 to 250 mg per week, with the stated goal of reaching 900 to 1,200 ng/dL or higher. The second is a man with a borderline level who is started at a dose far above what would be needed to correct it, and then titrated upward by symptoms that were never specific to testosterone in the first place.

Both are the same thing pharmacologically. You are adding androgen to a man who does not lack it, to push him above his own physiology. The Endocrine Society’s 2014 scientific statement on performance-enhancing drugs describes exactly this population and is blunt about who it is: “the vast majority of PED users are not athletes but rather nonathlete weightlifters, and the adverse health effects of PED use are greatly underappreciated.” [Pope et al., 2014]

The one real difference. I want to be fair about what the clinic actually provides. A prescription means a sterile, accurately dosed, pharmacy-sourced product instead of an underground lab vial of unknown concentration. It means bloodwork. It means someone notices when your hematocrit hits 56%. Those are not nothing, and harm reduction is a legitimate framework in medicine. But harm reduction is an argument for supervizing a risk, not a claim that the risk is gone, and it is not what is being advertised.

Where replacement ends: the dose-response data

We do not have to speculate about where the line sits. The question was answered directly by Bhasin’s dose-response work, which remains the cleanest human data we have on graded testosterone exposure.

Healthy young men received a GnRH agonist to shut down their own production, then weekly testosterone enanthate at 25, 50, 125, 300, or 600 mg for 20 weeks. The resulting mean nadir testosterone concentrations were 253, 306, 542, 1,345, and 2,370 ng/dL respectively. [Bhasin et al., 2001]

Read that series carefully, because it maps the entire argument.

Weekly doseMean nadir testosteroneChange in fat-free mass over 20 weeksWhere this sits
25 mg253 ng/dL−0.1 kgBelow the normal range
50 mg306 ng/dL+1.1 kgLow-normal
125 mg542 ng/dL+3.4 kgMid-normal: the replacement target
300 mg1,345 ng/dL+5.2 kgRoughly double the top of normal
600 mg2,370 ng/dL+7.9 kgFrank supraphysiologic exposure

Fat-free mass changes from Bhasin et al., 2001; nadir concentrations measured one week after the preceding injection, so peak levels were higher still.

Two things follow. The first is that about 125 mg per week lands a healthy man squarely in the middle of the normal range. That is what replacement looks like in a controlled setting. The companion trial in men aged 60 to 75 found the same thing and said so explicitly, concluding that the best trade-off between benefit and adverse effects was achieved at the 125 mg dose. [Bhasin et al., 2005]

The second is that the muscle keeps coming above that line. Fat-free mass rose from +3.4 kg at 125 mg to +7.9 kg at 600 mg. This is the uncomfortable part, and pretending otherwise destroys your credibility with anyone who has spent time in a gym: more androgen does build more muscle. It just does so by leaving the range the human body is built to run in, and everything else on the dose-response curve rises with it.

What the higher doses actually do

Red cells thicken the blood, predictably and by dose

Erythrocytosis is the most common dose-limiting effect of testosterone therapy. In the same dose-response cohorts, hemoglobin and hematocrit rose in a linear, dose-dependent fashion in both young and older men, and the effect was more pronounced with age. [Coviello et al., 2008] In the older cohort, several men had to be withdrawn for hematocrit above 54%; none of the young men crossed that threshold even at 600 mg weekly. [Bhasin et al., 2005] This is why 54% is the stop-and-reassess number in the guidelines, and it is the single most reliable consequence of pushing the dose up.

Fertility: suppression is the expected result, not a rare complication

The clearest data on this come from an unexpected source. The World Health Organization ran weekly 200 mg testosterone enanthate as a male contraceptive in a ten-center, seven-country trial of 271 healthy fertile men. By six months, 157 of them, a cumulative rate of 65%, had reached azoospermia on three consecutive semen samples, and the regimen was then used as the couples’ only form of contraception for twelve months. [WHO Task Force, Lancet 1990] The follow-up study across 15 centers found suppression to azoospermia or severe oligozoospermia in 97.8% of 399 men. [WHO Task Force, Fertil Steril 1996]

When a dose is effective enough at shutting down sperm production to be studied as birth control, calling that effect a side effect understates it. Median time from azoospermia back to a sperm concentration of at least 20 million/mL after stopping was 3.7 months in the 1990 trial, which is reassuring, but those were healthy men on a defined protocol for a defined period, not men three years into continuous use.

The same trial recorded gynecomastia in 24 of 271 men. [WHO Task Force, Fertil Steril 1996] Aromatization tracks total dose. More testosterone means more substrate.

The heart: the finding that changed my own thinking

Baggish and colleagues at Massachusetts General compared 86 long-term anabolic steroid users against 54 non-using weightlifters, all experienced lifters aged 34 to 54, using echocardiography and coronary CT angiography. Men who were on-drug at evaluation had meaningfully reduced left ventricular systolic function compared with non-users, with an ejection fraction of 49±10% versus 58±10%, along with reduced diastolic function. Users also carried greater coronary plaque volume than non-users, and, critically, lifetime cumulative dose was strongly associated with plaque burden. [Baggish et al., Circulation 2017]

That last clause is the one that matters for this discussion. A dose-response relationship with coronary atherosclerosis is not a finding you can supervise your way out of. It is an argument about total exposure over years, which is precisely what continuous “sports TRT” delivers, arguably more faithfully than a cycled approach does.

Imaging findings raise the question of whether events follow. A 2025 Danish registry study answered it by tracking cardiovascular diagnoses rather than scans, following men sanctioned for AAS use against age- and sex-matched controls over a mean of 11 years. The adjusted hazard ratios were not subtle: acute myocardial infarction 3.00 (95% CI 1.67 to 5.39), coronary intervention or bypass grafting 2.95, venous thromboembolism 2.42, and arrhythmia 2.26. [Windfeld-Mathiasen et al., Circulation 2025]

These men had a mean age around 27 at entry. A threefold rate of myocardial infarction in a cohort that young is not a subtle population signal. The same caveats apply as to any registry study, and one specific limitation matters here: the investigators could not track whether individuals continued using after their sanction, so the exposure is “ever sanctioned” not a measured dose over time.

Recovery is not guaranteed

A Danish case-control study compared 37 current users, 33 former users who had been off for a median of about 2.5 years, and 30 healthy controls. Former users still had significantly lower total testosterone than controls, 14.4 nmol/L (about 415 ng/dL) versus 18.8 nmol/L (about 542 ng/dL), and 27.2% of former users were below the lower reference limit years after stopping. [Rasmussen et al., PLoS One 2016]

Roughly one in four men who stopped had not gotten their own production back. This is the risk that is almost never priced into the decision at the front end, and it is the one that most often walks into my office: a man in his late thirties who started “optimization” at 32, stopped, and now needs genuine replacement for an iatrogenic deficiency he did not have before.

The population-level signal

Two Danish registry studies, built on men sanctioned for doping in fitness centers, give a view no clinic cohort can. In the first, 545 users matched to 5,450 controls, mortality was three times higher among users (HR 3.0, 95% CI 1.3 to 7.0), and acne, gynecomastia and erectile dysfunction each affected more than 10% of users. [Horwitz et al., J Intern Med 2019] The larger follow-up tracked 1,189 sanctioned men, mean age 27.4, against 59,450 controls over a mean of 11 years: 2.8% of users died versus 1% of controls, a hazard ratio of about 2.8, with hazard ratios of 3.6 for unnatural deaths and 2.2 for natural ones. [Windfeld-Mathiasen et al., JAMA 2024]

Read these honestly. These are observational cohorts of men sanctioned for doping, not of patients in supervised clinics. Confounding is substantial: risk-taking behavior, polypharmacy and other substance use plausibly drive a large share of the unnatural-death excess, and the authors say so. These studies cannot tell you the mortality risk of supervised supraphysiologic dosing. What they establish is that the population using these doses dies earlier, and that the gap is not small.

The part nobody puts in the advertisement

Everything above is a physical risk, and physical risks can be weighed. This one is different, because it changes who is doing the weighing.

Androgens produce a dependence syndrome. Reviewing seven studies, Kanayama, Brower, Wood, Hudson and Pope concluded that about 30% of illicit AAS users develop dependence, defined as continued use despite adverse effects on physical, psychosocial or occupational functioning. [Kanayama et al., Addiction 2009] An online survey of men active on bodybuilding and steroid forums found 23.4% of 479 users meeting dependence criteria. [de Zeeuw et al., Eur Addict Res 2023]

The mechanism is worth understanding, because it is not the one people expect. Androgens are not acutely intoxicating; nobody is chasing a high. The trap is built from the withdrawal state instead. Stopping leaves a man hypogonadal for weeks to months while his own axis recovers, and that state produces fatigue, low libido and genuine depressive symptoms. As the same group put it, men experiencing prolonged dysphoric effects or frank major depression from that withdrawal hypogonadism may desire to resume AAS, thus contributing to dependence. [Kanayama et al., Drug Alcohol Depend 2010]

Why this matters more, not less, in a clinic setting. A classic cycle has a built-in end date. A prescription renews. The commercial model that sells continuous “optimization” removes the natural off-ramp, and it does so for a drug where roughly a third of users struggle to stop, where stopping feels terrible, and where the person you would turn to for an honest assessment of whether you still need it is also the person billing you monthly for it. I am not alleging bad faith across an industry. I am pointing out an incentive structure that would concern us immediately in any other area of medicine.

If you want the plain test of whether this applies to you, it is not how much you take. It is how you feel about stopping. A man who can say “I would come off tomorrow if the labs said to” is in a different position from one who has already decided that is not on the table.

What TRAVERSE does and does not say

TRAVERSE is the trial that gets cited at me most often, usually incorrectly. It enrolled 5,198 men aged 45 to 80 with symptoms and two fasting testosterone levels below 300 ng/dL, all with existing or high risk of cardiovascular disease, and randomized them to transdermal testosterone titrated to 350 to 750 ng/dL or placebo. Major adverse cardiac events occurred in 7.0% of the testosterone group versus 7.3% on placebo (HR 0.96, 95% CI 0.78 to 1.17), meeting noninferiority. [Lincoff et al., NEJM 2023]

That is a genuinely important and reassuring result, and I use it to counsel patients who need treatment. But notice the three constraints built into it: diagnosed deficiency, a target inside the normal range, and a 33-month horizon. None of them describe sports TRT.

And even inside those constraints, the trial was not uniformly clean. Significantly more men on testosterone had atrial fibrillation (3.5% vs 2.4%, P=.02), acute kidney injury (2.3% vs 1.5%, P=.04), pulmonary embolism (0.9% vs 0.5%), and nonfatal arrhythmias warranting intervention (5.2% vs 3.3%, P=.001). The investigators wrote that these events were not expected. [Cleveland Clinic summary] The trial’s own lead authors cautioned that the findings “should not be used as a justification for widespread prescription of these products to large numbers of men.” [Cleveland Clinic newsroom, 2023]

Using a replacement-dose trial to vouch for performance dosing is a category error. If anything, the arrhythmia and thromboembolic signals at physiologic targets argue for more caution above them, not less.

The definition anti-doping bodies already use

There is one arena where this line has been drawn precisely, with money and careers on it, and it is worth knowing where it sits. Under WADA’s therapeutic use exemption framework, a TUE for testosterone is granted only for organic primary or secondary hypogonadism, a structural or genetic cause. Functional hypogonadism does not qualify. As the guidance is summarized for masters athletes: “TUE should only be approved for hypogonadism that has an organic etiology. TUE should not be approved for androgen deficiency due to functional disorder.” Andropause is explicitly not an acceptable diagnosis.

USADA’s physician worksheet is blunter still: low levels of an endogenous hormone “absent a defined organic etiology will not justify the granting of a TUE, even if within standard of care & prescribed by a physician.”

Read that last clause again, because it is the entire argument of this article stated by someone else: even if prescribed by a physician. Anti-doping authorities worked out decades ago that a prescription does not change what a substance does. They had to, because the alternative was a system where anyone with a sympathetic clinic could compete on exogenous androgen and call it medicine.

Why the clinic model is the thing to look at

It would be convenient to frame this as rogue operators versus real medicine. The more useful question is what the business model rewards, because that predicts the clinical behavior better than anyone’s intentions do.

Consider that the FDA’s own review of testosterone prescribing, the review that ultimately led it to mandate the TRAVERSE trial, found that “many men are treated with testosterone products even though their testosterone blood levels have never been checked.” That is the baseline problem in this field, and it predates the current wave of telehealth.

Now add a subscription structure. In a model where revenue depends on continuing therapy, four things tend to follow, and you can check any clinic against them:

  • The diagnostic threshold drifts upward. If 300 ng/dL disqualifies most prospective patients”optimal” ranges that start at 600 or 800 solve a business problem elegantly. Watch for any clinic whose stated target range has no source.
  • Symptoms do the diagnostic work. Fatigue, low mood, poor sleep and reduced libido are real, common, and caused by many things. A questionnaire that routes nearly everyone toward treatment is a sales funnel wearing a lab coat.
  • Reversible causes go unexamined. Treating the sleep apnea, the obesity, the alcohol intake or the untreated depression produces a patient who does not need a monthly prescription. That is a clinical success and a revenue loss.
  • Deprescribing never comes up. In legitimate practice”let’s see whether you still need this” is a routine sentence. Ask when you last heard it.

If you are evaluating a clinic, five questions will tell you most of what you need to know. What was my pre-treatment level, measured twice, in the morning? What is the target range you are treating me to, and whose guideline is that from? Did you check LH, FSH, SHBG and prolactin to find out why my level is low? What is your plan if my hematocrit reaches 54%? And if I want children in five years, what changes today?

A clinic practicing real medicine answers all five without friction. I would not stay at one that cannot.

The strongest case, both ways

The strongest case for the clinics

  • Men are going to use these drugs regardless. Supervision with real labs and pharmaceutical product is safer than an underground vial and a forum protocol.
  • The 300 ng/dL cutoff was derived largely from trials in men over 45 and fits a symptomatic 35-year-old poorly. A level of 320 is not automatically fine.
  • Continuous steady dosing avoids the post-cycle crash, which is when much of the psychiatric and cardiovascular turbulence of classic cycling appears.
  • Medicine has always treated conditions that sit on a spectrum rather than a cutoff, and the line at 300 is a convention, not a biological cliff.

Where that case breaks

  • Harm reduction describes supervizing a risk. It does not license marketing the result as a health intervention, which is what is happening.
  • The cutoff debate is an argument for better diagnosis, not for targeting 1,200 ng/dL. Nobody resolves a flawed threshold by tripling the target.
  • Continuous dosing means greater cumulative lifetime exposure, which is the variable Baggish found tracked with coronary plaque.
  • Roughly a quarter of former users had not recovered their own production years later. Started at 30, that is a four-decade prescription.
  • Roughly 30% develop dependence. A model with no end date and a monthly bill is poorly designed to catch that.

I hold both of these at once, and I think any honest clinician does. A man determined to use these compounds is better off with real labs, sterile product and a physician watching his hematocrit than with a forum protocol and a vial from a stranger. What I object to is not supervision. It is supervision marketed as optimization, which turns a risk being managed into a benefit being sold.

What I tell patients

I do not open with a lecture, because the man in front of me usually already knows what he is asking for. I work through four things.

First, get the diagnosis right. Two early-morning draws, fasting, on separate days, plus LH, FSH, SHBG, prolactin and a hematocrit. Free testosterone when SHBG is abnormal. A single afternoon total testosterone from a direct-to-consumer panel is not a diagnosis.

Second, treat the things that lower testosterone. Roughly half of men with obesity have reduced levels, [Cleveland Clinic J Med, 2024] and sleep apnea, alcohol, opioids, overtraining and untreated depression all pull the number down. Several of my patients who arrived asking for testosterone did not need it six months later.

Third, if you are deficient, treat properly. Lowest dose that reaches mid-normal, hematocrit and PSA on schedule, fertility discussed and hCG or a SERM considered before starting if children are a possibility, not after.

Fourth, if you want performance doses, I will tell you what they are. I am not going to pretend a 200 mg weekly protocol aimed at 1,100 ng/dL in a man with a baseline of 520 is replacement therapy. I will tell him it is a cycle, that it will likely suppress his fertility, that his hematocrit will climb, that a quarter of men in his position do not recover their own production, and that the cardiac data on long-term users is genuinely concerning. Then it is his decision, made with accurate information. That is a different conversation than the one he gets from an ad.

Bottom line

Testosterone replacement therapy is one of the more satisfying treatments in medicine when it is used for what it is for. A man with real deficiency, treated to a normal level and monitored properly, often gets his life back. I have watched it happen many times, and the TRAVERSE data should make physicians less skittish about providing it.

“Sports TRT” is a different product wearing that product’s clothes. The dose is above replacement, the indication is appearance and performance, and the clinical category it belongs to is supraphysiologic androgen use. You are allowed to make that choice as an adult. What you are not entitled to is the belief that a prescription repeals the dose-response curve.

References

  1. Mulhall JP, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. PubMed 29601923
  2. Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PubMed 29562364
  3. Bhasin S, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172-E1181. PubMed 11701431
  4. Bhasin S, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005;90(2):678-688. PubMed 15562020
  5. Coviello AD, et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914-919. PubMed 18160461
  6. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet. 1990;336(8721):955-959. PubMed 1977002
  7. World Health Organization Task Force. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril. 1996;65(4):821-829. PubMed 8654646
  8. World Health Organization Task Force. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. Fertil Steril. 1996;65(3):626-636. PubMed 8774299
  9. Baggish AL, et al. Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use. Circulation. 2017;135(21):1991-2002. PubMed 28533317 · PMC5614517
  10. Rasmussen JJ, et al. Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation. PLoS One. 2016;11(8):e0161208. PMC4988681
  11. Horwitz H, Andersen JT, Dalhoff KP. Health consequences of androgenic anabolic steroid use. J Intern Med. 2019;285(3):333-340. PubMed 30460728
  12. Windfeld-Mathiasen J, et al. Mortality Among Users of Anabolic Steroids. JAMA. 2024;331(14):1229-1230. JAMA
  13. Windfeld-Mathiasen J, et al. Cardiovascular Disease in Anabolic Androgenic Steroid Users. Circulation. 2025. doi:10.1161/CIRCULATIONAHA.124.071117. Record and abstract
  14. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG Jr. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009;104(12):1966-1978. PMC2780436
  15. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG Jr. Treatment of anabolic-androgenic steroid dependence: emerging evidence and its implications. Drug Alcohol Depend. 2010;109(1-3):6-13. PMC2875348
  16. de Zeeuw TI, Brunt TM, van Amsterdam J, et al. Anabolic Androgenic Steroid Use Patterns and Steroid Use Disorders in a Sample of Male Gym Visitors. Eur Addict Res. 2023;29(2):99-108. Karger
  17. Pope HG Jr, et al. Adverse Health Consequences of Performance-Enhancing Drugs: An Endocrine Society Scientific Statement. Endocr Rev. 2014;35(3):341-375. PubMed 24423981
  18. Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). N Engl J Med. 2023;389(2):107-117. NEJM · PubMed 37326322
  19. Testosterone deficiency diagnosis and thresholds. Cleve Clin J Med. 2024;91(2):93-95. CCJM
  20. WADA TUE Physician Guidelines, Male Hypogonadism; USADA Testosterone TUE Physician Worksheet. USADA worksheet · WMA summary of WADA TUEC guidelines

Educational content only. This article is not medical advice for any individual and does not establish a physician-patient relationship. Do not start, stop or change testosterone therapy without consulting your own physician. If you are currently on a supraphysiologic protocol, stopping abruptly carries its own risks and should be managed clinically.

Francisco Cardona, MD

Francisco Cardona, MD

Board-certified internal medicine physician in San Antonio and a retired IFBB Pro. I write about hormones, muscle and the distance between what the evidence says and what gets sold.

About meThe booksMore writing

Vita Nova Anti-Aging and Rejuvenation Center

If you want this applied to you rather than explained

I see patients in San Antonio: hormones, medical weight loss, sexual wellness, lasers and body contouring. Reading an article is not the same as being worked up properly. More about the clinic

Book an evaluation